These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 582411)
1. Plasma concentrations of isosorbide dinitrate after administration of increasing doses of a sustained-release formulation to human subjects. Taylor T; O'Kelly DA; Major RM; Darragh A; Chasseaud LF Arzneimittelforschung; 1978; 28(8):1426-8. PubMed ID: 582411 [TBL] [Abstract][Full Text] [Related]
2. Plasma concentrations of isosorbide dinitrate after oral administration of a sustained-release formulation to human subjects. Assinder DF; Chasseaud LF; Hunter JO; Jung RJ; Taylor T Arzneimittelforschung; 1977; 27(1):156-8. PubMed ID: 576817 [TBL] [Abstract][Full Text] [Related]
3. Plasma levels of isosorbide dinitrate and the isosorbide mononitrates after increasing doses of a retard preparation of isosorbide dinitrate. Bogaert MG; Rosseel MT Nouv Presse Med; 1980 Sep; 9(34 Suppl):2424-7. PubMed ID: 7422532 [TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of isosorbide dinitrate produced by a sustained-release capsule. Halkin H; Almog S; Friedman E Isr J Med Sci; 1979 May; 15(5):448-50. PubMed ID: 447513 [TBL] [Abstract][Full Text] [Related]
5. [Pharmacokinetics of 14C-isosorbide dinitrate after administration in various sustained-release formulations]. Chasseaud LF; Taylor T; Major RM; Taylor IW; Luckow V; Darragh A; Lambe RF Arzneimittelforschung; 1983; 33(9):1298-301. PubMed ID: 6685511 [TBL] [Abstract][Full Text] [Related]
6. [Assay of plasma isosorbide dinitrate and its metabolites after oral administration of immediate and delayed-action forms]. Audry E; Dallet P; Dubost JP; Langlois MH; Ernouf D; Narcisse G Ann Pharm Fr; 1989; 47(4):235-41. PubMed ID: 2637644 [TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate. Laufen H; Leitold M; Wildfeuer A Arzneimittelforschung; 1988 Sep; 38(9):1336-41. PubMed ID: 3223973 [TBL] [Abstract][Full Text] [Related]
8. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations. Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789 [TBL] [Abstract][Full Text] [Related]
9. Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations. Assinder DF; Chasseaud LF; Taylor T J Pharm Sci; 1977 Jun; 66(6):775-8. PubMed ID: 577507 [TBL] [Abstract][Full Text] [Related]
10. Plasma concentrations and bioavailability of isosorbide dinitrate and pindolol from a combination formulation. Chasseaud LF; Doyle E; Taylor T; Darragh A Biopharm Drug Dispos; 1981; 2(3):273-81. PubMed ID: 7295884 [TBL] [Abstract][Full Text] [Related]
11. [Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions]. Rietbrock N; Knoll J; Merz PG; Menke G Dtsch Med Wochenschr; 1985 Nov; 110(47):1821-5. PubMed ID: 3905327 [TBL] [Abstract][Full Text] [Related]
12. [Pharmacodynamic effects of the sustained-release tablet of isosorbide dinitrate and its bioavailability in conscious dogs (author's transl)]. Kogi K; Chida S; Kimura T; Saito T Nihon Yakurigaku Zasshi; 1980 Mar; 76(2):99-107. PubMed ID: 7399370 [TBL] [Abstract][Full Text] [Related]
13. Bioavailability of isosorbide dinitrate from an oral therapeutic system and from tablet Sorbonit Prolongatum 20,0 in human volunteers. Sawicki W; Deptulski T; Janicki S Pharmazie; 1989 Apr; 44(4):280-1. PubMed ID: 2772003 [TBL] [Abstract][Full Text] [Related]
14. [Bioavailability of isosorbide-5-mononitrate from delayed-action formulations]. Taylor T; Major RM; Leaf FC; Cook SC; Chasseaud LF; Darragh A; Lambe RF Arzneimittelforschung; 1984; 34(11):1584-7. PubMed ID: 6543135 [TBL] [Abstract][Full Text] [Related]
15. Plasma isosorbide dinitrate concentrations and effect after chewable and high-dose, sustained-release formulations. Galeazzi RL; Platzer R; Reutemann G Int J Clin Pharmacol Ther Toxicol; 1983 Aug; 21(8):387-93. PubMed ID: 6629543 [TBL] [Abstract][Full Text] [Related]
16. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate]. Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739 [TBL] [Abstract][Full Text] [Related]
17. Use of isosorbide dinitrate saliva concentrations for biopharmaceutical investigations. Laufen H; Schmid M; Leitold M J Pharm Sci; 1983 May; 72(5):496-9. PubMed ID: 6864494 [TBL] [Abstract][Full Text] [Related]
18. Plasma concentrations of isosorbide dinitrate after cutaneous and sublingual doses to human subjects. Mansel-Jones D; Taylor T; Doyle E; Chasseaud LF; Darragh A; O'Kelly DA; Over H J Clin Pharmacol; 1978; 18(11-12):544-8. PubMed ID: 721951 [TBL] [Abstract][Full Text] [Related]
19. Bioequivalence of a sustained-release isosorbide dinitrate formulation at steady-state. Taylor T; Chasseaud LF; Major RM; Leaf FC; Bonn R; Darragh A; Lambe RF Biopharm Drug Dispos; 1985; 6(2):119-29. PubMed ID: 4005392 [TBL] [Abstract][Full Text] [Related]
20. Plasma levels of isosorbide dinitrate and its main metabolites following oral administration of two sustained release formulations in normal man. Gladigau V; Neurath G; Dünger M; Schnelle K; Johnson KI Arzneimittelforschung; 1981; 31(5):835-40. PubMed ID: 7196746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]